In hepatocellular carcinoma (HCC), alternatively spliced variants of SLC22A1, encoding the organic cation transporter-1 (OCT1) caused decreased transport and sensitivity to sorafenib, the most common TKI used to treat advanced HCC [46]. Here, SLC22A1 is linked to hepatocellular carcinoma.